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significant difference between the treatments. There were no statistically significant 
differences between the groups neither in clinical symptoms nor in the number 
of doses of rescue medication. Due to deterioration of the disease five patients 
in the TBH group and four in the prednisolone group needed additional steroid 
treatment.
Conclusion: For follow-up treatment after an acute asthma attack inhaled steroids 
may substitute oral therapy.
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The Effectiveness of Inhaled Steroids as First-Line Therapy in the Treatment 
of Newly Detected Asthma in the Open Population 
P.R.S. Tirimanna 1. P.M. van Grunsven l , G, van den Boom l,21 C.P. van 
Schayck 1, H. Folgering-1, R.P. Akkermans 1, C.L.A. van Herwaarden\  C. van 
W eel1. 1 Department of General Practice, University of Nijmegen, The 
Netherlands; 2 Department o f Health Economics, University of Limburg, The 
Netherlands; ■* Department of Pulmonology, Dekkerswald, University of 
Nijmegen; The Netherlands
v
Introduction: Recent guidelines advise to start treatment with inhaled steroids in 
asthma in case of frequent symptoms or use of beta^-agonists. We investigated if 
inhaled steroids would also be effective as lirst-line treatment in asthma patients 
with no prior diagnosis of asthma.
Method: 54 Adult asthma patients were selected for participation in a randomized, 
double-blind, placebo-controlled trial. All patients had been detected by means of a 
screening procedure in 1155 randomly selected persons out of 10 general practices. 
They complied to the following inclusion cri le ri a for the trial (objective asthma 
criteria): FEV| (forced expiratory volume in one second) < reference value minus
2 standard deviations on at least two separate assessments 3 months apart or a 
PC^nhistamine <  2 mg/ml combined with a reversibility of the airway obstruction 
> 15% of the reference value, 31 subjects were willing to participate in this 1-yenr 
trial. The experimental group (15 patients) were treated with fluticasone propionate 
250 fig two times daily, the control group consisted of 16 patients. FEV¡ and 
PC20 were monitored once every three months, symptoms and peakflow weekly. 
The influence of fluticasone on the effect parameters was estimated by repeated 
measurement analyses.
Results: Patient characterics of both trial groups did not differ significantly at 
baseline. At the end of the trial the difference in FEVj was 76 ml in favour of 
the experimental group (p = 0.02). In the experimental group the PCin showed 
an improvement of 1.4 doubling doses (p = 0,002) during the trial. There was 110 
significant improvement in symptoms or peakflow but a tendency of improvement 
in number of exacerbation.
Conclusions: Inhaled steroids have shown to be effective as first-line therapy in 
newly detected asthma in the open population.
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The study compared the lung function response to salbutamol delivered via a 
novel DPI (Innovata Biomed Limited) and MDI (Ventolin ®, Allen and Hanburys), 
before and after use of the DPI during a 4-week open treatment period. A double 
blind, two way cross-over design was employed. Sixty two patients with mild to 
moderate asthma with FEV| reversibility (> 15% and > 200ml) to bronchodilator 
(200 /zg salbutamol or 500 fig terbutaline) were recruited. Spirometry (FEV|, 
F VC, PEFR) was performed following inhalation of 100 ¿¿g (at t = 0), 100 ßg  (at 
t ~  30 min) and 200 ¡ig (at t = 60 min) (equivalent to cumulative administration 
of 100, 200 and 400 /ig). increases in FEV¡ were similar following salbutamol 
via DPI or MDI (mean ±  SD difference 0 .0 1 dr 0,18 L). Following treatment with 
100 ¿tg salbutamol (the lowest dose deliverable by both devices), the increases 
in FEVj were also similar for both devices (mean ±  SD difference 0.01 ±  0.20 
L). Improvements in lung function were the same following treatment via DPI or 
MDI after the 4-week DPI treatment period. Heart rate and tremor recordings and 
adverse event reports were similar for the two treatments. These findings support 
the efficacy and safety of DPI, the therapeutic equivalence of DPI and MDI and 
the in-use stability of the DPI product.
P0395
Good Bronchodilating Effect of a Dry Powder Inhaler in the Treatment of 
Acute Asthma
P. Youngchaiyud N. Maranetra A. N ana1, S. Charoenratanakul \  J« Boe2, 
C-G. Löfdahl3, O. Selroos4, E, Stähl4. 1 Dept, o f Medicine, Siri raj Hospital, 
Bangkok, Thailand; 2 Rikshospitalet, Oslo, Norway; * University Hospital, Lund, 
Sweden; 4 Astra Draco AB, Lund, Sweden
Aim: To evaluate the efficacy of a dry powder inhaler, salbutamol Turbuhaler ® 
(TBH) in patients with acute bronchial obstruction attending the emergency room. 
The reference ding was salbutamol pressurized metered dose inhaler (pMDI) with 
spacer.
Design: Double-blind, randomized, parallel-group design with FEV¡ as the pri­
mary efficacy variable. Doses of 100 + 300 + 300 + 300 f i  g were given at 0, 15 ,30
and 45 min via TBH and repeated at 90, 105, 120 and 135 min, respectively (total 
2000 Mg)- The same inhalation schedule was followed for the pMDI with spacer 
but in double doses (total 4000 ßg). At S5 min after first dose 60 mg prednisolone 
was given orally. Peak inspiratory flow (PIF) through TBH was measured on each 
dosing occasion. Plasnia-salbutamol and serum-potassium concentrations were 
measured.
Patients; 86 patients (54 women), mean age 38 years, mean FEV| 37% predicted 
normal.
Results; No statistically significant differences were observed in the increase of 
FEV| between the groups: 55 min (165 min) after the first dose the mean increase 
was 47% (63%) in the TBH group and 42% (65%) in the pMDI group. Mean PIF 
through TBH was 49 (range 26-68) L/min at first inhalation and increased to 60 
(range 38-86) L/min. There was no correlation between the initial PIF through 
TBH and the FEV| response. The p-salbutamol and s-potassium values correlated 
well. Significant decrease in s-potassium in the pMDI group was noticed compared 
with the Turbuhaier group (p = 0.02).
Conclusion: A dry powder inhaler such as Turbuhaier can be used in acute asthma. 
Half the dose of salbutamol via Turbuhaier was as effective as the full dose given 
via pMDI with spacer.
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Aerosol delivery to the lungs of intubated patients is usually less than 10% when 
using a conventional nebulizer in the ventilator circuit (Crit Care Med 13: 81, 
1985). We have recently developed a 1 mm coaxial (OD) design catheter (Trudell 
Medical, London, Canada) which can be placed directly in the airways and produce 
an aerosol at its tip. Since the upper airway (and endotracheal tube) are bypassed 
by this catheter, optimal particle sizing for lung deposition might be different than 
that expected for conventional aerosol generators external to the patient. To predict 
aerosol deposition in the lung from this catheter when positioned just above the 
carina, we developed a computer model of the lung based upon the morphometric 
data of Wetbel, Ventilation parameters were: tidal volume 900 ml, inspiratory and 
expiratory time of 3 sec each, and a constant inspiratory flow pattern. Data was 
generated for particle sizes of 2.5, 5, 7.5 and 10 micron MMD. Deposition was 
calculated as a fraction of total aerosol generated:
Particle size
i f im)
Percent deposition
Large airways Small airways Alveoli Total
2,5 7.1 14.6 36.1 57.8
5 22.9 31.3 26.8 81.2
7,5 43.7 35.6 9.5 88.9
10 63.7 26.3 1.7 91.8
We conclude that overall deposition and optimal particle size distributions for this 
system are different from that obtained from conventional systems external to the 
patient.
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A recent report by the audit commission [1] questioned the large increase in 
the prescribing of dry-powder devices in primary care asthma management and 
whether this use was appropriate. Clinical experience in our practice suggested 
that many patients appeared to be happier with dry-powder devices and appeared 
to have better asthma control with them. As a result our prescribing of dry-powder 
inhaled steroids has increased from £561 in 1987 to £21635 in 1994 a forty-fold 
increase. This level of prescribing was subject to significant questioning. To assess 
whether there was any benefit in their use we looked at patients changed to one 
dry-powder device the turbohaler.
Methods: We audited measured outcomes and asthma management costs in 32 pa­
tients who had been changed from a metered dose inhaler (MDI) to the turbohaler 
for their inhaled prophylaxis.
Results: In those changed to the budesonide turbohaler we found a 19% reduction 
in bronchodilator use from the year before to the year after starting it, a 57% 
reduction in prednisolone courses for the treatment of exacerbations and a 35% 
reduction in GP & nurse visits.
These improvements were achieved at an increased cost of £82 per patient per 
annum when all health-care costs were taken into account.
Conclusions: This audit would suggest that changing from MDls to the dry-powder 
device, budesonide turbohaler was effective for the outcomes measured.
[I] A prescription for improvement: towards more rational prescribing in general practico. HMSO. 
1994
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